$219 Million is the total value of Asymmetry Capital Management, L.P.'s 33 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 85.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTRS | New | Viatris Inc | $21,186,000 | – | 1,130,504 | +100.0% | 9.66% | – |
| SAGE | Buy | SAGE THERAPEUTICS INC | $15,715,000 | +151.0% | 181,650 | +77.3% | 7.17% | +78.0% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $14,836,000 | +809.1% | 89,889 | +685.3% | 6.76% | +544.9% |
| PODD | Buy | INSULET CORP | $11,663,000 | +19.8% | 45,624 | +10.9% | 5.32% | -15.0% |
| NSTG | Buy | NANOSTRING TECHNOLOGIES INC | $11,561,000 | +60.4% | 172,862 | +7.2% | 5.27% | +13.8% |
| KURA | Buy | KURA ONCOLOGY INC | $11,317,000 | +84.2% | 346,518 | +72.8% | 5.16% | +30.7% |
| GH | Buy | GUARDANT HEALTH INC | $10,212,000 | +32.7% | 79,239 | +15.1% | 4.66% | -5.9% |
| BDSX | New | BIODESIX INC | $9,656,000 | – | 478,985 | +100.0% | 4.40% | – |
| FLDM | Buy | FLUIDIGM CORP | $9,269,000 | +27.5% | 1,544,904 | +57.9% | 4.23% | -9.5% |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $9,045,000 | +308.9% | 348,408 | +170.0% | 4.12% | +190.0% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $7,779,000 | +11.5% | 101,245 | +8.5% | 3.55% | -20.9% |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $7,734,000 | – | 88,195 | +100.0% | 3.53% | – |
| CDXS | New | CODEXIS INC | $6,953,000 | – | 318,492 | +100.0% | 3.17% | – |
| AVDL | Buy | AVADEL PHARMACEUTICALS PLCadr | $6,385,000 | +143.2% | 955,856 | +83.5% | 2.91% | +72.6% |
| PMVP | Buy | PMV PHARMACEUTICALS INC | $5,942,000 | +572.2% | 96,595 | +288.1% | 2.71% | +376.9% |
| TXG | Sell | 10X GENOMICS INC-CLASS A | $5,322,000 | -1.9% | 37,587 | -13.6% | 2.43% | -30.4% |
| BNR | Buy | BURNING ROCK BIOTECH LTD-ADRadr | $5,030,000 | -7.7% | 217,728 | +0.2% | 2.29% | -34.5% |
| ITOS | Buy | ITEOS THERAPEUTICS INC | $4,680,000 | +228.4% | 138,384 | +139.6% | 2.13% | +133.0% |
| CCCC | New | C4 THERAPEUTICS INC | $4,616,000 | – | 139,343 | +100.0% | 2.10% | – |
| FATE | Sell | FATE THERAPEUTICS INC | $4,611,000 | +1.8% | 50,709 | -55.3% | 2.10% | -27.8% |
| VTGN | New | VISTAGEN THERAPEUTICS INC | $4,345,000 | – | 2,239,803 | +100.0% | 1.98% | – |
| GLTO | New | GALECTO INC | $4,220,000 | – | 337,352 | +100.0% | 1.92% | – |
| ITCI | New | INTRA-CELLULAR THERAPIES INC | $4,155,000 | – | 130,654 | +100.0% | 1.90% | – |
| BMYRT | Buy | BRISTOL-MYERS SQUIBB-CVRrts | $3,555,000 | +1.3% | 5,152,098 | +230.2% | 1.62% | -28.2% |
| STRO | New | SUTRO BIOPHARMA INC | $3,421,000 | – | 157,583 | +100.0% | 1.56% | – |
| FBRX | Buy | FORTE BIOSCIENCES INC | $3,094,000 | -20.1% | 84,989 | +6.5% | 1.41% | -43.3% |
| NCNA | Buy | NUCANA PLC-ADRadr | $2,756,000 | +3.7% | 613,769 | +19.4% | 1.26% | -26.4% |
| MREO | New | MEREO BIOPHARMA GROUP PL-ADR | $2,649,000 | – | 739,812 | +100.0% | 1.21% | – |
| ORIC | New | ORIC PHARMACEUTICALS INC | $2,275,000 | – | 67,210 | +100.0% | 1.04% | – |
| WVE | New | WAVE LIFE SCIENCES PTE LTD | $2,211,000 | – | 280,924 | +100.0% | 1.01% | – |
| NVUS | Sell | NOVUS THERAPEUTICS INC | $1,233,000 | +19.2% | 80,069 | -92.6% | 0.56% | -15.5% |
| BLSA | New | BCLS ACQUISITION CORP- CL A | $993,000 | – | 89,135 | +100.0% | 0.45% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC. | $891,000 | – | 46,910 | +100.0% | 0.41% | – |
| SELB | Exit | SELECTA BIOSCIENCES INC | $0 | – | -55,343 | -100.0% | -0.09% | – |
| EQ | Exit | EQUILLIUM INC | $0 | – | -143,543 | -100.0% | -0.53% | – |
| GRAY | Exit | GRAYBUG VISION INC | $0 | – | -92,159 | -100.0% | -0.75% | – |
| FSDC | Exit | FS DEVELOPMENT CORP-A | $0 | – | -193,728 | -100.0% | -1.39% | – |
| MEIP | Exit | MEI PHARMA INC | $0 | – | -787,359 | -100.0% | -1.58% | – |
| PACB | Exit | PACIFIC BIOSCIENCES OF CALIF | $0 | – | -257,044 | -100.0% | -1.63% | – |
| TPTX | Exit | TURNING POINT THERAPEUTICS I | $0 | – | -36,571 | -100.0% | -2.05% | – |
| ATRS | Exit | ANTARES PHARMA INC | $0 | – | -1,194,530 | -100.0% | -2.07% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PLC | $0 | – | -51,995 | -100.0% | -2.60% | – |
| UNH | Exit | UNITEDHEALTH GROUP INC | $0 | – | -18,666 | -100.0% | -3.74% | – |
| ILMN | Exit | ILLUMINA INC | $0 | – | -20,451 | -100.0% | -4.06% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -340,253 | -100.0% | -4.74% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -155,232 | -100.0% | -5.50% | – |
| QDEL | Exit | QUIDEL CORP | $0 | – | -39,314 | -100.0% | -5.54% | – |
| ASND | Exit | ASCENDIS PHARMA A/S - ADRadr | $0 | – | -81,442 | -100.0% | -8.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.